The purpose of this study was to examine the immunoexpression of cell adhesion molecules (CAMs) E-cadherin, CD44s, and CD44v3 in cervical cancer and compare it with that in benign exo-endocervical tissue. In all, 81 cervical cancer biopsy specimens and 22 benign controls were included. Primary monoclonal antibodies NHC-38, F10-44-2, and 3G5 for E-cadherin, CD44s, and CD44v3 were used, respectively. Statistical significance was evaluated by the χ2 test. Antigen expression was significantly different in cervical cancer specimens compared with controls, showing marked decrease in membrane expression: E-cadherin, 6.5% and 77.3% (P < .000); CD44s, 3.9% and 81.8% (P < .000); and CD44v3, 0% and 81.8% (P < .000), respectively. The immunoexpression was significantly heterogeneous in carcinomas (P < .034) and adenocarcinomas (P < .000) for E-cadherin and CD44s. For CD44v3, no case of cancer showed immunostaining in membranes. These findings reaffirm that cell adhesion is markedly altered in cervical cancer. The authors suggest that these proteins could serve as markers for invasive cervical neoplasia.
GumbinerBM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996;84: 345-357.
2.
HirohashiS. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153:333-339.
3.
HanahanDWeinbergR. The hallmark of cancer. Cell. 2000;100:57-70.
4.
IvanovDBPhilippovaMPTkachukVA. Structure and functions of classical cadherins. Biochemistry. 2001;66: 1174-1186.
5.
HongSCSongJYLeeJKLeeNWKimSHYeomBWLeeKW. Significance of CD44v6 expression in gynecologic malignancies. J Obstet Gynaecol Res. 2006;32: 379-386.
6.
HagaTUchideNTugizovSPalefskyJM. Role ofE-cadherin in the induction of apoptosis of HPV16-positive CaSki cervical cancer cells during multicellular tumor spheroid formation. Apoptosis. 2008;13:97-108.
7.
ChenCLLliuSSIpSMWongLCNgTYNganHY. E-E-cadherin expression is silenced by DNA methylation in cervical cancer cell lines and tumours. Eur J Cancer. 2003;39:517-523.
8.
De BoerCVan DorstEVan KriekenH. Changing roles of cadherinas and catenins during progression of squamous intraepithelial lesions in the uterine cervix. Am J Pathol. 1999;155:505-515.
9.
TolgCHofmannMHerrlichPPontaH. Splicing choice from ten variant exons establishes CD44 variability. Nucleic Acids Res. 1993;21:1225-1229.
10.
ShiozakiHOkaHInoueMTamuraSMondenM. E-cadherin mediated adhesion system in cancer cell. Cancer. 1996;77(8 suppl):1605-1613.
11.
ShimabukuroKToyamo-SorimachiNOzakiY. The expression patterns of standard and variant CD44 molecules in benign uterine cervix and cervical cancer. Gynecol Oncol. 1997;64:26-34.
12.
VesseyCJWildingJFolarinN. Altered expression and function of E-cadherin in cervical intraepithelial neoplasia and invasive squamous cell carcinoma. J Pathol. 1995;176:151-159.
13.
DaraïEWalker-CombrouzeFBéniflaJ-L. E-cadherin and CD44 expression in cervical intraepithelial neoplasia:comparison between HIV-positive and HIV-negative women and correlation with HPV status. Gynecol Oncol. 2000;76:56-62.
14.
Faleiro-RodriguesCLopesC. E-cadherin, CD44 and CD44v6 in squamous intraepithelial lesions and invasive carcinomas of the uterine cervix: an immunohistochemical study. Pathobiology. 2004;71:329-336.
15.
HeatleyMK. E-cadherin and expression in benign and neoplastic endocervical glandular epithelium. Histopathology. 2004;45:201-202.
16.
VandePutteGKristensenGBBaekelandTMLieAKHolmR. E-cadherin and catenins in early squamous cervical carcinoma. Gynecol Oncol. 2004;94:521-527.
17.
Rodríguez-SastreMGonzález-MayaLDelgadoR. A benign distribution of E-cadherina and beta-catetina in different histologic types of cancer of the uterine cervix. Gynecol Oncol. 2005;97:330-336.
18.
HondaS. Immunohistochemical study on the expression of E-cadherin in benign tissues and squamous cell carcinomas of the uterine cervix. Nippon Sanka Fujinka Gakkai Zasshi. 1992;44:517-523.
19.
SunHLiuXLiM. E-E-cadherin expression and its clinical significance in cervical cancer. Zhonghua Zhong Liu Za Zhi. 2000;22:496-498.
20.
WuHLotanRMenterDLippmanSMXuXC. Expression of E-cadherin is associated with squamous differentiation in squamous carcinomas. Anticancer Res. 2000;20(3A):1385-1390.
21.
DanielBRangarajanAMukherjeeGVallikadEKrishnaS. The link between integration and expression of human papillomavirus type 16 genomes and cellular changes in the evolution of cervical intraepithelial neoplastic lesions. J Gen Virol. 1997;78:1095-1101.
22.
WrightTCFerenczyAKurmanRJ. Carcinoma and other tumors of the cervix. In: KurmanRJ, ed. Blaustein’s Pathology of the Female Genital Tract. 4th ed.New York, NY: Springer-Verlag; 1994:279-326.
23.
HanACEdelsonMIPralta SolerA. E-cadherin expression in glandular tumors of the cervix. Cancer. 2000;89:2053-2058.
24.
CaricoEAtlanteMBucciBNofroniIVecchioneA. E-cadherin and alfa-catenin expression during tumor progression of cervical carcinoma. Gynecol Oncol. 2001; 80:156-161.
25.
KawanishiJJKatoJSasakiKFujiiSWatanabeNNitsuY. Loss of E-cadherin dependent cell-cell adhesion due to mutation of the β-catenin gene in a human cancer cell line HSC-39. Mol Cell Biol. 1995;15:1175-1181.
26.
ChenYTStewartDBNelsonWJ. Coupling assembly of the E-cadherin/ β-catenin complex to efficient endoplasmic reticulum exit and basal-lateral membrane targeting ofE-cadherin in polarized MDCK cells. J Cell Biol. 1999; 144:687-699.
27.
HuberAHStewartDBLaurentsDYNelsonWJWeisWI. The cadherin cytoplasmic domain is unstructured in the absence of β-catenin. J Biol Chem. 2001;276: 12301-12309.
28.
MakrydimasGZagorianakouNZagorianakouPAgnantisNJ. CD44 family and gynaecological cancer. In Vivo. 2003;17:633-640.
29.
KuoKTLiangCWHsiaoCH. Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol. 2006;19:1570-1577.
30.
DallPHeiderKHHekeleA. Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and benign cervical epithelium. Cancer Res. 1994;54:3337-3341.
31.
GorhamHWoodmanAGoodisonS. CD44 expression in cervical intraepithelial neoplasia (CIN) and carcinoma. Mol Diagn. 1999;4:45-56.
32.
SaegusaMHashimuraMMachidaDOkayasuI. Down-regulation of CD44 standard and variant isoforms during the development and progression of uterine cervical tumours. Pathology. 1999;187:173-183.
33.
DavidsonBGoldbergIGotliebWHBen-BaruchGKopolovicJ. CD44 expression in uterine cervical intraepithelial neoplasia and squamous cell carcinoma: animmunohistochemical study. Eur J Gynaecol Oncol. 1998;19:46-49.
34.
LuDTawfikOPantazisCHobartWChapmanJIczkowskiK. Altered expression of CD44 and variantisoforms in human adenocarcinoma of the endocervix during progression. Gynaecol Oncol. 1999;75:84-90.
35.
WoernerSMGivehchianMDurstM. Expression of CD44 splice variants in benign, dysplastic, and neoplastic cervical epithelium. Clin Cancer Res. 1995;1: 1125-1132.
36.
IbrahimEMBlackettADTidyJAWellsM. CD44 is a marker of endocervical neoplasia. Int J Gynecol Pathol. 1999;18:101-108.
